Dyne Therapeutics, Inc.·4

Mar 10, 5:33 PM ET

Posner Brian S 4

4 · Dyne Therapeutics, Inc. · Filed Mar 10, 2026

Research Summary

AI-generated summary of this filing

Updated

Dyne Therapeutics Director Brian Posner Buys 3,000 Shares

What Happened

  • Brian S. Posner, a director of Dyne Therapeutics (DYN), purchased 3,000 shares in an open-market transaction on March 6, 2026. The reported weighted-average price was $15.06 per share, for a total reported purchase value of $45,180. This was a purchase (insider acquisition), which some investors view as more informative than routine sales, though motives are not disclosed.

Key Details

  • Transaction date: 2026-03-06
  • Transaction type/code: Open-market purchase (P)
  • Price: Weighted average $15.06; actual trades ranged $14.96–$15.12 (footnote)
  • Total value: $45,180
  • Shares owned after transaction: Not disclosed in the provided filing
  • Filing date/timeliness: Form 4 filed 2026-03-10 (filed within the SEC’s required 2 business days)
  • Footnote: The $15.06 price is a weighted average; the filing states trades occurred at prices between $14.96 and $15.12 and that the reporting person will provide a breakdown on request.

Context

  • This was an open-market purchase of common stock (code P). No option exercises, gifts, or 10b5-1 plans are referenced in the provided information. Purchases by directors are factual data points for investors but do not, by themselves, explain the insider’s motivation.

Insider Transaction Report

Form 4
Period: 2026-03-06
Transactions
  • Purchase

    Common Stock

    [F1]
    2026-03-06$15.06/sh+3,000$45,18011,500 total
Footnotes (1)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices within the range of $14.96 to $15.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
Signature
/s/ Ron Caponigro, Attorney-in-Fact|2026-03-10

Documents

1 file
  • 4
    ownership.xmlPrimary

    4